Table 1.
Summary of the main studies on conventionally fractionated and hypofractionated RT in older patients. Survival outcomes and complications are reported. Abbreviations: P prospective, R retrospective, NSCLC non-small cell lung cancer, MIBC muscle invasive bladder cancer, BCC basal cell carcinoma, CFRT conventional fractionated radiotherapy, HFRT hypofractionated radiation therapy, FU follow-up, OS overall survival, RFS recurrence-free survival, LC local control, BCF biochemical or clinical failure, GI gastrointestinal, GU genitourinary.
| Authors | Year | Type of study | N. Pts |
Median age (range) | Histology | Type of RT | Dose range Gy/fxs | Median FU (months) | Outcomes | Acute toxicities (%) | Late toxicities (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pergolizzi et al. [22] | 2002 | P | 40 | 77 (75–83) | NSCLC | CFRT | 54-64/27-32 | 54 | Median OS 19 months | G1/2 esophagitis (70) | Radiation pneumonia (5) |
| Santacaterina et al. [24] | 2002 | R | 45 | 75 (70–85) | MIBC | CFRT | 56-64/28-32 | 63 | Median OS 21.5 months | G1/2 GI and/or GU toxicity (100) | - |
| Santacaterina et al. [25] | 2015 | R | 27 | 84.5 (81–91) | MIBC | CFRT | 60-64/30-32 | 17.5 | Mean OS 23.5 months | G1/2 GI and/or GU toxicity (55.5) | G1/2 GI and/or GU toxicity (11) |
| Wujanto et al. [27] | 2019 | R | 45 | 77 (65–95) | MIBC | CFRT | 50–69.8/30-40 | 31 | Median OS 56 months | G1/2 GI and/or GU toxicity (89) | G3 cystitis (2.2) |
| Soyfer et al. [60] | 2013 | R | 21 | 80 | Soft-tissue sarcoma | HFRT | 39-48/13-16 | 26 | - | G2/3 toxicity (3.75) | G2/3 toxicity (3.75) |
| Kouloulias et al. [30] | 2014 | R | 38 | 78 (64–91) | BCC | HFRT | 30/5 once weekly | 48 | Local RFS 92.1% | G1/2 skin toxicity (92.2) | - |
| Marriappan et al. [31] | 2014 | R | 25 | 89 (83–103) | BCC | HFRT | 42/7 once weekly | 15 | LC 95% | - | - |
| Pelissero et al. [33] | 2015 | R | 117 | 82 (75–103) | BCC | HFRT | 25-30/5–6 once weekly | 61 | 3-year RFS 96.4%; 5-year RFS 94.5% |
G1/2 skin toxicity (30.7) | - |
| Russi et al. [32] | 2015 | R | 134 | 82.5 (75–103) | BCC | HFRT | 25-30/5–6 once weekly | 64.5 | 3-year RFS 97.3%; 5-year RFS 92.7% |
G1/2 skin toxicity (30.6) | - |
| Dirix et al. [34] | 2016 | R | 44 | 72 | MIBC | HFRT | 34.5/6 | 10 | Mean OS 10.5 months; mean hematuria-free survival 13 months | G3 GU toxicity (9) | G3 GU toxicity (19) |
| Sanz et al. [28] | 2018 | R | 486 | 79 | Breast cancer | HFRT | 30–37.5/6 | 51 | 5-year OS 74.2%; local RFS 96.5% | G1 dermatitis (52) | G1 fibrosis (68) |
| Wilson et al. [29] | 2018 | P | 491 | 75 | Prostate cancer | HFRT | 57-60/19-20 | 60 | 5-year BCF-free rates 87.7–91% | G3 GI and/or GU toxicity (10) | G2 GI toxicity (12.5) and GU toxicity (9.2) |
| Hammer et al. [35] | 2019 | R | 17 | 87 (81–95) | MIBC | HFRT | 45/15 | 65.3 | 1-year OS 47%; 2-year OS 23% |
G3 GI toxicity (6) and GU toxicity (24) | G3 GU toxicity (5.8) |